| Nov 15 |
Kodiak: Tarcocimab Faces High Barriers To Entry Despite Resurrection (Rating Upgrade)
|
| Nov 15 |
Kodiak Q3 Loss Narrower Than Expected, Pipeline Development in Focus
|
| Nov 14 |
Kodiak Sciences GAAP EPS of -$0.84 beats by $0.07
|
| Nov 14 |
Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2024 Financial Results
|
| Nov 11 |
Kodiak Sciences to Participate in Upcoming Investor Conferences
|
| Oct 21 |
3 US Penny Stocks With Market Caps Under $500M To Consider
|
| Oct 14 |
Kodiak Sciences to Present at Innovate Retina 2024
|
| Oct 10 |
Kodiak Counts on Tarcocimab Eye Disease Program Despite Setbacks
|
| Sep 23 |
Kodiak Sciences to Host Investor R&D Day Today at 10:30am Eastern Time
|
| Sep 18 |
We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully
|
